Novavax Incorporation announced on Monday that its combined flu and COVID-19 vaccine elicited working antibodies against the viruses in a preclinical study.
Novavax Incorporation announced on Monday that its combined flu and COVID-19 vaccine elicited working antibodies against the viruses in a preclinical study. The NanoFlu/NVX-CoV2373 vaccine elicited strong responses to both influenza A and B and protected against the SARS-CoV-2 virus.1
"Seasonal influenza and COVID-19 combination vaccines will likely be critical to combating emerging COVID-19 variants," said Russell Wilson, Novavax Executive Vice President, NanoFlu General Manager.
Animals who received the combined vaccine showed heightened levels of COVID-19 antibodies two weeks after their first immunization. This increased significantly after a second dose, compared to animals that received the COVID-19 vaccine, NVX-CoV2373, alone, the company said. Novavax said it expects to start clinical studies of the combined vaccine by the end of 2021.1-3
References
FDA Issues CRL for Heplisav-B in Adults With ESRD on Hemodialyis
May 14th 2024Dynavax plans to meet with the FDA to discuss how the company can provide additional data to support the approval of its 4-dose Heplisav-B regimen and expand protection for adults with end-stage renal disease (ESRD) on hemodialysis.